Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Bosutinib

    Client Email Product

    Bosutinib

    APIs // Active Pharmaceutical Ingredients

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    7
    US DMFs Filed

    US DMFs Filed

    5
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    2
    Other Suppliers

    Other Suppliers

    3
    API REF. PRICE (USD / KG)
    6,217

    API Market Place

    2
    INTERMEDIATES
    10
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    0

    Europe

    Europe

    6
    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    1
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    373.00

    Annual Reports

    375.00

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    2

    News

    17
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    2
    SERVICES

    0

    Full View ScreenFull Screen View
    FDA approves decade-old Pfizer drug for rare childhood leukemia
    FDA approves decade-old Pfizer drug for rare childhood leukemia

    https://endpts.com/fda-approves-decade-old-pfizer-drug-for-rare-childhood-leukemia/

    Nicole DeFeudis ENDPTS
    28 Sep 2023
    Share Share
    Amber Specialty Added to Pfizer’s Limited Distribution Network
    Amber Specialty Added to Pfizer’s Limited Distribution Network

    https://www.businesswire.com/news/home/20220803005649/en

    BUSINESSWIRE
    03 Aug 2022
    Share Share
    Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR
    Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR

    https://www.prnewswire.com/news-releases/novartis-investigational-stamp-inhibitor-asciminib-abl001-shows-superior-mmr-rate-to-bosulif-in-chronic-myeloid-leukemia-trial-301188521.html

    PRNEWSWIRE
    08 Dec 2020
    Share Share
    Novartis’ phase III ASCEMBL study of asciminib vs bosutinib meets primary
    Novartis’ phase III ASCEMBL study of asciminib vs bosutinib meets primary

    http://www.pharmabiz.com/NewsDetails.aspx?aid=130660&sid=2

    PHARMABIZ
    26 Aug 2020
    Share Share
    List of Paragraph IV Patent Certifications (PPIV) as of December 3, 2018
    List of Paragraph IV Patent Certifications (PPIV) as of December 3, 2018

    https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM293268.pdf

    FDA
    12 Dec 2018
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Bosulif 203341 (Bosutinib) Tablets
    FDA Confirms Paragraph IV Patent Challenge of Bosulif 203341 (Bosutinib) Tablets

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-bosulif-203341-bosutinib-extended-release-tablets-1544700147.pdf

    FDA
    12 Dec 2018
    Share Share
    Biogen, Ionis collaborate to identify therapies to treat spinal muscular atrophy
    Biogen, Ionis collaborate to identify therapies to treat spinal muscular atrophy

    http://www.pharmabiz.com/NewsDetails.aspx?aid=106277&sid=2

    PHARMABIZ
    20 Dec 2017
    Share Share
    Avillion Announces US Approval of Pfizer's BOSULIF® (bosutinib)
    Avillion Announces US Approval of Pfizer's BOSULIF® (bosutinib)

    https://www.prnewswire.com/news-releases/avillion-announces-us-approval-of-pfizers-bosulif-bosutinib-for-the-treatment-of-patients-with-newly-diagnosed-ph-chronic-myelogenous-leukemia-cml-665271693.html

    PR NEWSWIRE
    19 Dec 2017
    Share Share
    Pfizer, Avillion file for Bosulif expansion
    Pfizer, Avillion file for Bosulif expansion

    http://www.pharmatimes.com/news/pfizer,_avillion_file_for_bosulif_expansion_1203702

    Selina McKee PHARMA TIMES
    31 Aug 2017
    Share Share
    U.S. FDA & EMA Accept Regulatory Submissions for BOSULIF® (bosutinib)
    U.S. FDA & EMA Accept Regulatory Submissions for BOSULIF® (bosutinib)

    http://www.businesswire.com/news/home/20170829005234/en/U.S.-FDA-European-Medicines-Agency-Accept-Regulatory/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    29 Aug 2017
    Share Share
    NICE backs routine use of Incyte’s leukaemia drug
    NICE backs routine use of Incyte’s leukaemia drug

    http://www.pharmatimes.com/news/nice_backs_routine_use_of_incytes_leukaemia_drug_1186477

    Selina McKee PHARMATIMES
    14 Feb 2017
    Share Share
    Pfizer Reports Positive Top-Line Results For Phase 3 BFORE Study Of BOSULIF
    Pfizer Reports Positive Top-Line Results For Phase 3 BFORE Study Of BOSULIF

    http://www.nasdaq.com/article/pfizer-reports-positive-topline-results-for-phase-3-bfore-study-of-bosulif-20161205-00385

    NASDAQ
    06 Dec 2016
    Share Share
    NICE expands NHS treatment options for CML, lung cancer
    NICE expands NHS treatment options for CML, lung cancer

    http://www.pharmatimes.com/news/nice_expands_nhs_treatment_options_for_cml,_lung_cancer_1110539

    Selina McKee PHARMATIMES
    25 Aug 2016
    Share Share
    BCR-ABL Tyrosine Kinase Inhibitors - Risk of Hepatitis B Reactivation
    BCR-ABL Tyrosine Kinase Inhibitors - Risk of Hepatitis B Reactivation

    http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-eng.php

    HEALTH CANADA
    06 May 2016
    Share Share
    Health Canada Require Updated Warning on Gleevec Labeling for Brand and Generics
    Health Canada Require Updated Warning on Gleevec Labeling for Brand and Generics

    http://twofourinsight.com/health-canadarequires-warning-gleevec-labeling-brand-generics/

    TWOFOUR INSIGHT
    05 May 2016
    Share Share
    BCR-ABL Tyrosine Kinase Inhibitors
    BCR-ABL Tyrosine Kinase Inhibitors

    http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-eng.php

    HEALTH CANADA
    04 May 2016
    Share Share
    Twenty-three therapies axed from Cancer Drugs Fund
    Twenty-three therapies axed from Cancer Drugs Fund

    http://www.pharmatimes.com/Article/15-09-06/Twenty-three_therapies_axed_from_Cancer_Drugs_Fund.aspx

    Selina McKee PHARMATIMES
    08 Sep 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search